Key Takeaways Increasing competition from alternative ablation technologies and pricing pressures from hospital consolidations could limit both revenue growth and margin improvement. High R&D investments and regulatory challenges risk eroding operating leverage, even as new products and international expansion drive sales.Read more
Key Takeaways Accelerated adoption of innovative minimally invasive devices and successful product launches are driving strong revenue growth, profitability, and operating leverage. Global market expansion, advancing clinical trials, and robust evidence generation are broadening access, supporting payer acceptance, and positioning for sustained long-term growth.Read more
Key Takeaways Surgeons' rapid adoption of differentiated devices and expanding clinical trial indications are propelling AtriCure toward market dominance and sustained revenue growth. International expansion, operational efficiencies, and favorable industry tailwinds position AtriCure for durable margin expansion and outsized earnings growth.Read more
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
